The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 05, 2021

Filed:

Jan. 10, 2017
Applicants:

British Columbia Cancer Agency Branch, Vancouver, CA;

The University of British Columbia, Vancouver, CA;

Inventors:

Francois Benard, Vancouver, CA;

Kuo-shyan Lin, Surrey, CA;

David Perrin, Vancouver, CA;

Zhibo Liu, Beijing, CN;

Hsiou-ting Kuo, Vancouver, CA;

Jinhe Pan, Richmond, CA;

Aron Roxin, Norman, OK (US);

Mathieu Lepage, Vancouver, CA;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); C07F 5/02 (2006.01); A61K 51/04 (2006.01); C07F 5/00 (2006.01); A61P 35/00 (2006.01); C07B 59/00 (2006.01);
U.S. Cl.
CPC ...
C07F 5/027 (2013.01); A61K 51/0402 (2013.01); A61K 51/0453 (2013.01); A61K 51/0455 (2013.01); A61K 51/0497 (2013.01); A61P 35/00 (2018.01); C07B 59/004 (2013.01); C07F 5/003 (2013.01); C07B 2200/05 (2013.01);
Abstract

This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R)CHBF, a pyridinium group substituted with BFor methyl BF, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.


Find Patent Forward Citations

Loading…